文献速递妇科

DCVAC/OvCa联合二线化疗治疗铂敏感卵巢癌的随机II期试验

Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.
PubMed 文献 · Gynecol Oncol · 2021-07-20

这项开放标签、平行组II期试验纳入71例一线化疗后复发的铂敏感卵巢癌患者,随机接受DCVAC/OvCa联合卡铂和吉西他滨或单纯化疗。DCVAC/OvCa未改善无进展生存(HR 0.73,95%CI 0.42-1.28,P=0.274),但中位总生存显著延长13.4个月(HR 0.38,95%CI 0.20-0.74,P=0.003),且安全性良好。

要点

  • DCVAC/OvCa联合化疗未改善铂敏感卵巢癌患者的PFS。
  • DCVAC/OvCa组中位OS显著延长13.4个月(HR 0.38,P=0.003)。
  • DCVAC/OvCa联合化疗安全性良好,并观察到抗原特异性T细胞活性增强信号。

核心结论

  • DCVAC/OvCa联合化疗在铂敏感卵巢癌中安全性良好,未改善PFS,但探索性分析显示OS延长和 surrogate 抗原特异性T细胞活性增强。

研究设计与样本

  • 开放标签、平行组、随机II期试验(NCT02107950),纳入71例一线化疗后复发的铂敏感卵巢癌患者,随机分配至DCVAC/OvCa联合化疗组或单纯化疗组。

主要发现

  • DCVAC/OvCa组中7例因未接受至少1剂DCVAC/OvCa被排除主要疗效分析。
  • PFS未改善:HR 0.73,95%CI 0.42-1.28,P=0.274,数据成熟度78.1%。
  • 中位OS显著延长13.4个月:HR 0.38,95%CI 0.20-0.74,P=0.003,数据成熟度56.3%。
  • DCVAC/OvCa相关治疗中出现不良事件发生于6例(16.2%),白细胞分离相关2例(5.4%),化疗相关35例(94.6%);化疗组所有患者发生化疗相关事件。
  • 观察到DCVAC/OvCa增强 surrogate 抗原特异性T细胞活性的信号。

临床怎么用

  • 对于铂敏感复发性卵巢癌,DCVAC/OvCa联合卡铂和吉西他滨安全性可接受,但PFS未获益,OS延长为探索性结果,需进一步验证。

局限性

  • 样本量小(71例),为II期试验,OS数据成熟度56.3%,OS延长为探索性分析,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: DCVAC/OvCa is an active cellular immunotherapy designed to stimulate an immune response against ovarian cancer. We explored the safety and efficacy of DCVAC/OvCa plus carboplatin and gemcitabine in platinum-sensitive ovarian cancer. METHODS: In this open-label, parallel-group, phase 2 trial (ClinicalTrials.gov number NCT02107950), patients with platinum-sensitive ovarian cancer relapsing after first-line chemotherapy were randomized to DCVAC/OvCa and chemotherapy or chemotherapy alone. DCVAC/OvCa was administered every 3-6 weeks (10 doses). Endpoints included safety, progression-free survival (PFS; primary efficacy endpoint) and overall survival (OS; secondary efficacy endpoint). RESULTS: Between November 2013 and May 2015, 71 patients were randomized to chemotherapy in combination with DCVAC/OvCa or to chemotherapy alone. Treatment-emergent adverse events related to DCVAC/OvCa, leukapheresis and chemotherapy occurred in six (16.2%), two (5.4%), and 35 (94.6%) patients in the DCVAC/OvCa group. Chemotherapy-related events occurred in all patients in the chemotherapy group. Seven patients in the DCVAC/OvCa group were excluded from primary efficacy analyses due to failure to receive ≥1 dose of DCVAC/OvCa. PFS was not improved (hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.42-1.28, P = 0.274, data maturity 78.1%). Median OS was significantly prolonged (by 13.4 months) in the DCVAC/OvCa group (HR 0.38, 95% CI 0.20-0.74, P = 0.003; data maturity 56.3%). A signal for enhanced surrogate antigen-specific T-cell activity was seen with DCVAC/OvCa. CONCLUSIONS: DCVAC/OvCa combined with chemotherapy had a favorable safety profile in patients with platinum-sensitive ovarian cancer. DCVAC/OvCa did not improve PFS, but the exploratory analyses revealed OS prolongation and enhanced surrogate antigen-specific T-cell activity.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Cibula D, Rob L, Mallmann P, et al. Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial. Gynecol Oncol. 2021. PMID: 34294416. doi:10.1016/j.ygyno.2021.07.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。